首页> 外文期刊>ACS medicinal chemistry letters >Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents
【24h】

Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents

机译:秋水仙碱结合位点作为潜在抗癌药的吲哚衍生物的结构优化

获取原文
获取原文并翻译 | 示例
       

摘要

A new series of indole analogues based on our earlier lead compound, 2-(1H-indol-5-yl)-4-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-c]pyridine (42), was prepared as tubulin inhibitors in an effort to find a molecule with improved cytotoxic potency and metabolic stability. A series of indolyl-imidazopyridines (IIP) were synthesized and exhibited potent tubulin polymerization inhibitory activity with potent IC50 values ranging from 3 to 175 nM against a panel of human melanoma and prostate cancer cell lines. Among these compounds, the 6-indolyl compound 43 showed improved cytotoxic potency (average IC50 of 9.75 nM vs 55.75 nM) and metabolic stability in human liver microsomes (half-life time was 56.3 min vs. 45.4 min) as compared to previously reported 42. It was also shown to be effective against P-glycoprotein (P-gp) mediated multiple drug resistance (MDR) and taxol resistance.
机译:基于我们之前的先导化合物2-(1H-吲哚-5-基)-4-(3,4,5-三甲氧基苯基)-1H-咪唑并[4,5-c]吡啶的一系列新的吲哚类似物(42为了寻找一种具有改善的细胞毒性和代谢稳定性的分子,制备了一种作为微管蛋白抑制剂的药物。合成了一系列吲哚基-咪唑并吡啶(IIP),并显示出有效的微管蛋白聚合抑制活性,针对一组人黑素瘤和前列腺癌细胞系的有效IC50值范围为3至175 nM。在这些化合物中,6-吲哚基化合物43与先前报道的42相比,在人肝微粒体中显示出更高的细胞毒性(IC50为9.75 nM vs. 55.75 nM)和代谢稳定性(半衰期为56.3 min vs. 45.4 min)。它也被证明对P-糖蛋白(P-gp)介导的多重耐药性(MDR)和紫杉醇耐药性有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号